Pimecrolimus Cream 1% for Treatment of Vulvar Lichen Simplex Chronicus: An Open-Label, Preliminary TrialGoldstein A.T. · Parneix-Spake A. · McCormick C.L. · Burrows L.J.
aDivision of Gynecologic Specialties, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, Md., and bNovartis Pharmaceuticals Corp., East Hanover, N.J., USA
Background: To evaluate efficacy and safety of pimecrolimus cream 1% twice daily for treatment of vulvar lichen simplex chronicus (LSC). Methods: Patients in this 12-week, open-label study had biopsy-proven vulvar LSC. Inclusion criteria were patient-reported Visual Analog Scale for Pruritus Relief ≧3 (VAS-PR, 0 cm = no itching to 10 cm = severe itching) and Investigator’s Global Assessment ≧2 (IGA, 0 = no disease to 3 = severe disease). Safety was evaluated by adverse event reports and pimecrolimus blood level measurements. Results: Twelve women aged 25–53 years were enrolled. The median pruritus score (VAS-PR) decreased from 6 (min. 4.9, max. 9.0) at baseline to 0 cm at week 4 (max. 4.2), week 8 (max. 3.1) and week 12 (max. 2.1). Seven patients reported complete resolution of pruritus by week 4. Median IGA decreased from 2.5 (min. 2, max. 3) at baseline to 0 (min. 0, max. 2) at week 12. Erythema, excoriation, and lichenification improved for all patients. Pimecrolimus blood concentration for all samples was below the limit of quantification, 0.3 ng/ml. No adverse events were reported. Conclusions: In this exploratory study, signs and symptoms of vulvar LSC improved for all women and pimecrolimus cream showed a favorable safety profile. Larger prospective studies are needed to further evaluate pimecrolimus for treatment of vulvar LSC.
Andrew T. Goldstein, MD FACOG
Director, The Centers for Vulvovaginal Disorders
3 Washington Circle NW, Suite 205
Washington, DC 20037 (USA)
Tel. +1 202 887 0568, Fax +1 410 757 8741, E-Mail firstname.lastname@example.org
This research was presented at the 2006 Annual Meeting of the American Academy of Dermatology and also accepted as a poster presentation for the 2006 Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
Received: April 4, 2006
Accepted after revision: November 1, 2006
Published online: July 27, 2007
Number of Print Pages : 7
Number of Figures : 2, Number of Tables : 1, Number of References : 24
Gynecologic and Obstetric Investigation
Vol. 64, No. 4, Year 2007 (Cover Date: November 2007)
Journal Editor: D'Hooghe, T. (Leuven)
ISSN: 0378–7346 (print), 1423–002X (Online)
For additional information: http://www.karger.com/GOI